Adam B. Weiner, MD (@adam_weiner535) 's Twitter Profile
Adam B. Weiner, MD

@adam_weiner535

@CedarsSinai + @UclaUrology @UroOnc ♋️🧬|Supporting editor @EUplatinum📝|Formerly: @NM_Urology @Uchipritzker @Yale ‘12| @abhita_reddy=No one can do it better❤️

ID: 23269670

linkhttps://www.ncbi.nlm.nih.gov/myncbi/12AgCapNreHQ4/bibliography/public/ calendar_today08-03-2009 03:12:17

2,2K Tweet

2,2K Followers

1,1K Following

Adam B. Weiner, MD (@adam_weiner535) 's Twitter Profile Photo

🚨“What Happened to Getting a Doctor’s Finger in Your Butt?” 🗞️Slate ✍🏼 Dan Kois Dan Stone, MD & I weigh in on the waning role of the rectal exam 👉to screen for #prostatecancer 💡#TLDR 1️⃣ “You’re not shortchanging them of care!”… if you skip the exam However… 2️⃣“If

Eric Li (@ericliuro) 's Twitter Profile Photo

🚨New Publication🚨 -12.8% iPCa, 4.4% >GG2 (n=811) -PHI >55 associated with iPCa -Pre op PIRADS 4-5, neg biopsy with 95% NPV for iPCa -Most iPCa is low volume GG1 managed with active surveillance, n=3 further PCa treatment doi.org/10.1002/pros.2… Amy Krambeck NM Urology

Adam B. Weiner, MD (@adam_weiner535) 's Twitter Profile Photo

🚨 Ex vivo screening with patient-derived organoids for #bladdercancer🚨 Just out in European Urology 🔬A step forward in precision oncology 🧬Individualizing care for patients based on ex vivo drug sensitivity 👏Aaron Udager, MD, PhD U-M Rogel Cancer Center 🔗tinyurl.com/yc6h5f3r

🚨 Ex vivo screening with patient-derived organoids for #bladdercancer🚨

Just out in <a href="/EUplatinum/">European Urology</a> 

🔬A step forward in precision oncology

🧬Individualizing  care for patients based on ex vivo drug sensitivity 

👏<a href="/AUdager66035/">Aaron Udager, MD, PhD</a> <a href="/UMRogelCancer/">U-M Rogel Cancer Center</a>

🔗tinyurl.com/yc6h5f3r
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

1/ Results from #LITESPARK-005 are out NEJM! The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) U.S. FDA approval Dec 2023 in pretreated pts w/ #ccRCC. Presentation #ESMO24 @myEsmo Check it out: nejm.org/doi/full/10.10…

1/ Results from #LITESPARK-005 are out <a href="/NEJM/">NEJM</a>! 
The phase 3 trial that led to HIF-2 inhibitor Belzutifan (BEL) <a href="/US_FDA/">U.S. FDA</a> approval Dec 2023 in pretreated pts w/ #ccRCC. 
Presentation #ESMO24 @myEsmo

Check it out: nejm.org/doi/full/10.10…
Adam B. Weiner, MD (@adam_weiner535) 's Twitter Profile Photo

Too many reasons to choose urology! 1) Great surgeries 😷 2) opportunities to teach 👨‍🏫 3) fulfilling pt interactions 🤝 And who doesn’t love a simple prostatectomy? Amer. Urol. Assn. NM Urology UCLA Urology Urology Graduate Medical Education at Cedars-Sinai #urosome

Too many reasons to choose urology!

1) Great surgeries 😷
2) opportunities to teach 👨‍🏫
3) fulfilling pt interactions 🤝

And who doesn’t love a simple prostatectomy?

<a href="/AmerUrological/">Amer. Urol. Assn.</a> <a href="/NM_Urology/">NM Urology</a> <a href="/UclaUrology/">UCLA Urology</a> <a href="/UroResidentsCS/">Urology Graduate Medical Education at Cedars-Sinai</a> #urosome
Adam B. Weiner, MD (@adam_weiner535) 's Twitter Profile Photo

🚨Olaparib for high-risk Biochemically Recurrent #ProstateCancer🚨 JAMA Oncology ✅51 pts w/ BCR after prostatectomy (PSADT<6mo) 💊Olaparib monotheray, NO ADT!!!! 50% PSA decline: 👉Nearly half of pts w/ HRR alterations 👉All pts w/ BCRA2 alterations had a PSA50 response

🚨Olaparib  for high-risk Biochemically Recurrent #ProstateCancer🚨

<a href="/JAMAOnc/">JAMA Oncology</a> 

✅51 pts w/ BCR after prostatectomy (PSADT&lt;6mo)

💊Olaparib monotheray, NO ADT!!!!

50% PSA decline:
👉Nearly half of pts w/ HRR alterations
👉All pts w/ BCRA2 alterations had a PSA50 response
Ronac Mamtani (@ron_cology) 's Twitter Profile Photo

We've had no data on real-world EV+P use for mUC, until now. In European Urology we show rapid dissemination of EV+P in practice. As of 3/31/24, <4 mo after U.S. FDA full approval, EV+P accounted for ~50% of 1L tx starts, supplanting platinum-chemo (23%). authors.elsevier.com/a/1jeFg14kplyy…

We've had no data on real-world EV+P use for mUC, until now. In <a href="/EUplatinum/">European Urology</a> we show rapid dissemination of EV+P in practice. As of 3/31/24, &lt;4 mo after <a href="/US_FDA/">U.S. FDA</a> full approval, EV+P accounted for ~50% of 1L tx starts, supplanting platinum-chemo (23%). 
authors.elsevier.com/a/1jeFg14kplyy…
Adam B. Weiner, MD (@adam_weiner535) 's Twitter Profile Photo

🚨Suicide Attempt & Suicide Death Among Spouses of Patients with Cancer🚨 JAMA Oncology 👉Danish study of >400k spouses of patients w/ cancer Higher risk of both: 1⃣Suicide attempts (HR 1.28) & 2⃣Suicide deaths (HR 1.47) 🛑A poignant reminder for those treating cancer of the

🚨Suicide Attempt &amp; Suicide Death Among Spouses of Patients with Cancer🚨

<a href="/JAMAOnc/">JAMA Oncology</a> 

👉Danish study of &gt;400k spouses of patients w/ cancer

Higher risk of both:
1⃣Suicide attempts (HR 1.28) 
&amp;
2⃣Suicide deaths (HR 1.47)

🛑A poignant reminder for those treating cancer of the
Rishi Sekar (@rishisekarmd) 's Twitter Profile Photo

Where our patients live and characteristics of their community play an important role in the experience of cancer-related financial hardship. Really enjoyed working on this project with Michigan Urology chief resident and future YUO Urology@UNC fellow Apoorv Dhir.

Adam B. Weiner, MD (@adam_weiner535) 's Twitter Profile Photo

🚨Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant #ProstateCancer JAMA Network Open Cohort study, pts w/ nmCRPC n=870 Compared with Apa and Enza, Darolutamide a/w... 1⃣Longer time on therapy 2⃣Longer time to metastatic progression 3⃣Fewer

🚨Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant #ProstateCancer

<a href="/JAMANetworkOpen/">JAMA Network Open</a> 

Cohort study, pts w/ nmCRPC n=870

Compared with Apa and Enza, Darolutamide a/w...
1⃣Longer time on therapy
2⃣Longer time to metastatic progression
3⃣Fewer
Jeremy Teoh (@jteoh_hk) 's Twitter Profile Photo

Dear friends, I’m trying very hard to help a group of young talents from the UAA Young Leadership Forum. They are keen to do some research work and they have compiled a survey on the Role of AI in Urology. Appreciate your help on this, thanks! forms.gle/9HfsaodwsB4vh3…

Rishi Sekar (@rishisekarmd) 's Twitter Profile Photo

Barriers to clinical trials participation are often rooted in social determinants of health. But what matters more, characteristics of the individual or the community they reside in? Lindsey Herrel Kristian Stensland, MD MPH Avi Maganty MD Nat’l Clinician Scholars Program at U-M IHPI U-M IHPI Michigan Urology ascopubs.org/doi/10.1200/OP…

Urology Care Foundation (@urologycarefdn) 's Twitter Profile Photo

🔍 Let's bust some myths! In today's Urology Mythbusters, we clear up common misconceptions and bring you the truth. 💡 This episode features Justin Dubin, MD & Rachel S. Rubin, MD #UrologyMythbusters #Urology

Urology Care Foundation (@urologycarefdn) 's Twitter Profile Photo

Did you know half the men over the age of 40 have experienced sexual dysfunction? 🍆 Thank you Raevti Bole, MD for talking about #SexualHealthAwarenessMonth, and helping us break the stigma around talking about your sexual health. Click the link to learn more ➡️ bit.ly/3ZbDslj